eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
NOWOŚĆ
Portal dla gastroenterologów!
www.egastroenterologia.pl
SCImago Journal & Country Rank
4/2017
vol. 12
 
Poleć ten artykuł:
Udostępnij:
więcej
 
 
streszczenie artykułu:
Artykuł przeglądowy

Management of anemia in inflammatory bowel disease: a challenge in everyday clinical practice

Edyta Tulewicz-Marti, Andrzej Moniuszko, Grażyna Rydzewska

Data publikacji online: 2017/12/14
Pełna treść artykułu
Pobierz cytowanie
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 


Anemia is the most common extraintestinal manifestation and complication of inflammatory bowel disease (IBD). Its etiology is multifactorial and mostly is a combination of iron deficiency anemia (IDA) and chronic anemia (ACD). Because of its high incidence in patients with IBD and its influence on their quality of life, regular screening is recommended. In case of IDA type of medication and route of administration should be determined by many factors such as general condition of the patient, IBD activity or anemia severity. Intravenous iron supplementation is the preferred route but may be associated with phosphate drop or even severe hypophosphatemia (HP). The mechanism of HP related to the intravenous iron infusions is not clearly known yet, but it might be related to the change of FGF-23 levels. What more not all parenteral forms of iron are equal and some may have a higher risk of HP than others.
referencje:
Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 2013; 10: 585-95.
Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn’s disease. Aliment Pharmacol Ther 2006; 24: 1507-23.
Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anaemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004; 116 Suppl 7A: 44S-9S.
Burisch J, Vegh Z, Katsanos KH, et al. Occurrence of anaemia in the first year of inflammatory bowel disease in a European population-based Inception Cohort – An ECCO-EpiCom Study. J Crohns Colitis 2017; 11: 1213-22.
Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006; 12: 123-30.
Pizzi LT, Weston CM, Goldfarb NI, et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 47-52.
Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006; 12: 123-30.
Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity WHO/NMH/NHD/MNM/11.1.
Stein J, Hartman F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 599-610.
Wiskin AE, Fleming BJ, Wootton SA, et al. Anaemia and iron deficiency in children with inflammatory bowel disease. J Crohns Colitis 2012; 6: 687-91.
Goodhand JR, Kamperidis N, Rao A, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica 2010; 95: 199-205.
Wilkholm E, Malmborg P, Forssberg M, et al. Iron deficiency is common during remission in children with inflammatory bowel disease. Glob Pediatr Health 2016; 3: 2333794X16633672.
Dignass AU, Gasche C, Bettenworth D, et al. European Consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9: 211-22.
Kaniewska M, Bartnik W, Gonciarz M, et al. Iron deficiency anaemia in patients with inflammatory bowel disease: National Consultant for Gastroenterology Working Group Recommendations. Prz Gastroenterol 2014; 9: 259-63.
Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: regulation of mammalian iron metabolism. Cell 2010; 142: 24-38.
Brunner AV, Joffe A, Duggan AK, et al. Randomised study of cognitive effects of iron supplementation in non-anemic iron-deficient adolescent girls. Lancet 1996; 348: 992-6.
Chavarro JE, Rich-Edwards JW, Rosner BA, et al. Iron intake and risk of ovulatory infertility. Obstet Gynecol 2006; 108: 1145-52.
Krayenbuehl PA, Battegay E, Breymann C, et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011; 118: 3222-7.
Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-23.
Bregman DB, Morris D, Koch TA, et al. Hepcidin levels predicts nonresponsiveness to oral. Am J Hematol 2013; 88: 97-101.
Elena E, Gregory K, Judy H, et al. Intravenous iron replacement improves quality of life in hypoferritinemic inflammatory bowel disease patients with and without anemia. Dig Dis 2017; 35: 444-8.
Zimmermann MB, Chassard J, Rohner F, et al. The effects of iron fortification on the gut microbiota in African children: randomized control trial in Cote d’Ivoire. Am J Clin Nutr 2010; 92: 1406-15.
Nielsen O, Ainsworth M, Coskun M, et al. Management of iron-deficiency anemia in inflammatory bowel disease: a systemic review. Medicine 2015; 94: e963.
Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr 1970; 100: 301-3.
Evstatiev R, Alexeeva O, Bokemeyer B, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 269-77.
Rognoni C, Venturini S, Meregaglia M, et al. Efficacy and safety of ferric carboxymaltose and other formulations in iron-deficient patients: a systemic review and network meta-analysis of randomised controlled trials. Clin Drug Investig 2016; 36: 177-94.
Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol 2015; 2015: 468675.
Bager P, Hvas C, Dahlerup J. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol 2017; 83: 1118-25.
Farrow EG, Yu X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 2011; 108: E1146-55.
Okada M, Imamura K, Fuchigami T, et al. Two cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide. Nihon Naika Gekkai Zasshi 1982; 71: 1566-72.
Schaefer B, Würtinger P, Finkenstedt A, et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS One 2016; 11: e0167146.
Bishay R, Granada K, Seibel M. Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature. Ther Adv Endocrinol Metab 2017; 8: 14-9.
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe